8th Annual Summit on Biosimilars
Event Jun 12 - Jun 14, 2017
Location: New York, NY, USA
With four biosimilars now approved in the U.S. and many more applications currently before the FDA, the business of biosimilars seemed to be in full swing in 2016. Now, due to a new administration and the potential repeal of the ACA, the future of biosimilars is currently uncertain.
There has never been a more critical time to hear insider insights from industry authorities on the status of the biosimilars business today and discuss strategies with your peers on what the next steps are given the potentially game-changing legal developments ahead.